FDA delayed fast-track reviews for multiple drugs after safety and efficacy concerns, including adverse events and a reported ...
Eli Lilly and Co. is preparing for a massive rollout of its highly anticipated weight-loss pill, orforglipron, after receiving fast-track regulatory review by the U.S. Food and Drug Administration.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback